Clinical Trials | March 17, 2026
Eli Lilly’s EBGLYSS shows breakthrough results in children with severe eczema
The company announced positive topline data from the Phase 3 ADorable-1 trial
The company announced positive topline data from the Phase 3 ADorable-1 trial
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
